/Viatris%20Inc%20logo%20on%20building-by%20SSKH-Pictures%20via%20Shutterstock.jpg)
Due to Viatris’ underperformance relative to the broader S&P 500 Index over the past year, Wall Street analysts remain cautious about the stock’s prospects.
The earnings season for the drug/biotech sector is now in its final lap, with some large biotech and generic drug companies due to report their third-quarter 2024 results this week.The remaining large...
Viatris is all set to announce its third-quarter results next month, with analysts predicting a double-digit decline in the company's earnings.
Explore why traditional value investing often falls short and how catalysts can transform undervalued stocks into lucrative investments.
CVS just announced it was considering a breakup. Why is that important? Spinoffs are one of the best-kept investment secrets, despite the fact that many investors typically disregard them and frequently...
Viatris has underperformed the Dow Jones Industrial Average over the past year, and analysts remain cautious about the stock’s prospects.
Investors in Viatris Inc. VTRS need to pay close attention to the stock based on moves in the options market lately. That is because the Jan 17, 2025 $3 Call had some of the highest implied volatility...
Value stocks offer potential for significant returns in today's overheated market.